Abcam, ab263183, Human EIF4G2 (P97/DAP5) knockout HEK-293T cell lysate

Size: 1Kit
EIF4G2 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 128 bp insertion in exon3.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 128 bp insertion in exon3.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-EIF4G2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The P97/DAP5 protein also known as eukaryotic initiation factor 4 gamma 2 (eIF4G2) functions mechanically as a translational regulator. It has a significant role in the process of cap-independent translation where it helps to assemble the initiation complex required for the translation of specific mRNAs. P97/DAP5 has a molecular mass of approximately 97 kDa. It is widely expressed across various tissues including high levels in both neuronal and non-neuronal cells which indicates its importance in fundamental cellular processes.
Biological function summary
P97/DAP5 impacts translation initiation by interacting with components of the translation machinery. It is part of a multiprotein complex where it binds to other translation initiation factors. Unlike eIF4G1 P97/DAP5 operates in conditions where cap-dependent translation is downregulated such as during cellular stress. This activity highlights its role in selectively activating the translation of mRNAs that are important for cell survival and adaptation during times of cellular distress.
Pathways
P97/DAP5 plays critical roles in the cellular stress response and apoptosis pathways. In the stress response pathway it is instrumental in shifting translation from a cap-dependent to cap-independent mechanism often in cooperation with proteins like eIF4B. In the apoptosis pathway it modulates the translation of apoptotic factors. These functions ensure cells maintain protein synthesis under adverse conditions maintaining cellular viability and regulating programmed cell death.
P97/DAP5 has links to cancer and neurodegenerative diseases. Alterations in the function or expression of P97/DAP5 can contribute to oncogenesis by allowing cancer cells to survive under stress conditions like hypoxia. It is also related to neurodegenerative disorders due to its significant expression in neurons with dysregulation possibly impacting neuronal survival. Proteins such as eIF4A interplay with P97/DAP5 in these diseases underlining its potential as a therapeutic target.